ABSTRACT. Macrophages remove deteriorating cells (those undergoing apoptosis and oxidation) via poly-Nacetyllactosaminyl chains on CD43 caps, a major cell-surface glycoprotein. Unusually high intracellular calcium levels are also deteriorating for cells and tissue. Here we artificially elevated calcium levels in cells and examined the mechanism by which this elevation was resolved by macrophages. Results showed that treatment with the calcium ionophore A23187 and ionomycin induces capping of CD43 on Jurkat cells, which are subsequently recognized and phagocytosed by macrophages, indicating that macrophages regard cells with elevated calcium as targets for removal. Further tests showed that A23187-and ionomycin-treated Jurkat cells did not induce apoptotic changes such as DNA fragmentation or phosphatidylserine expression, indicating that these cells were removed despite still being viable. Jurkat cells pretreated with anti-CD43 antibody or those with poly-Nacetyllactosaminyl chains containing oligosaccharides inhibited macrophage binding, indicating that macrophages recognize the poly-N-acetyllactosaminyl chains on CD43. Binding was also inhibited by treating macrophages with anti-nucleolin antibody, indicating that recognition occurs through nucleolin, a cell-surface receptor. Further, nucleolin-transfected HEK293 cells bound A23187-treated cells, and this binding was inhibited by in the presence of oligosaccharides. Taken together, these results show that elevated calcium levels induce CD43 capping, and macrophages remove the cells if their nucleolin receptors can bind to the poly-Nacetyllactosaminyl chains of capped CD43.
Introduction
Deteriorating cells, including those undergoing apoptosis, oxidation, and senescence are rapidly recognized and ingested by macrophages before they collapse and release harmful intracellular contents (Aderem and Underhill, 1999; Hanayama et al., 2004; Maderna and Godson, 2003; Ren and Savill, 1998; Savill and Fadok, 2000) . If these cells are not removed, the contents injure surrounding tissue and induce abnormal autoimmune responses, potentially triggering any of several functional disorders (Aderem and Underhill, 1999; Hanayama et al., 2004; Maderna and Godson, 2003; Ren and Savill, 1998; Savill and Fadok, 2000) . Macrophages also suppress inflammation by inhibiting pro-inflammatory cytokine production and releasing anti-inflammatory cytokines Maderna and Godson, 2003; Ren and Savill, 1998; Savill and Fadok, 2000) and are therefore critical for maintaining homeostasis and healthy tissue by safely clearing deteriorating cells and reducing inflammation. Hypercalcemia and unusually high intracellular calcium levels are also deteriorating condition for cells and tissue, because unusually high intracellular calcium levels disrupt host homeostasis (Legrand, 2011; Kim et al., 2002; McConkey et al., 1989b McConkey et al., , 1989a . However, physiological defense mechanism for unusual calciumelevation was poorly understood. Present study investigated that the removal mechanism of calcium-elevated cells by macrophages.
Successful removal of deteriorating cells (those undergoing apoptosis, oxidation, and senescence) depends on the interaction between their cell-surface ligands and corresponding macrophage receptors, several of which have been reported, including phosphatidylserine (PS) and carbohy-drate chains (Savill et al., 1993; Savill and Fadok, 2000; Fadok et al., 2001; Platt et al., 1998; Eda et al., 2004) . PS is a well-known ligand located on deteriorating cells, and several receptors for it have been found on macrophages, including CD36 (Rigotti et al., 1995) , CD68 (Sambrano and Steinberg, 1995) , lectin-like oxidized low-density lipoprotein receptor 1 (Oka et al., 1998) , Tim-4 (Miyanishi et al., 2007) , and stabillin-2 (Park et al., 2008) . Additionally, conserved motifs on deteriorating cells are recognized by the mannose receptor (Aderem and Underhill, 1999; Ogden et al., 2001) .
Although the mechanism by which macrophages recognize carbohydrate ligands on deteriorating cells is not fully understood, our previous studies have shed considerable light on the process (Ando et al., 2000; Eda et al., 2004; Miki et al., 2009; Beppu et al., 1996a) . Deteriorating cells undergo capping by the membrane glycoprotein CD43, and macrophages recognize these cells through the cluster of poly-N-acetyllactosaminyl chains that become available when CD43 caps are formed (Eda et al., 2004; Miki et al., 2009) . In a previous study, we identified nucleolin, a multifunctional shuttle protein, as the macrophage receptor for these carbohydrate chains on apoptotic and oxidized cells (Hirano et al., 2005; Miki et al., 2009) .
CD43 capping is thought to occur as follows: CD43 normally binds the cytoskeleton protein actin (Fukuda, 1996; Ostberg et al., 1998) , and capping occurs when this bond is broken by caspases in the early stages of apoptosis (Kondo et al., 1997; Eda et al., 2004; Miki et al., 2009) . Indeed, CD43 capping has been induced artificially using inhibitors that block actin and microtubule polymerization (Oguri et al., 2012; Seveau et al., 1997) . CD43 may be conjugated to several cytoskeleton proteins, and disrupting the actin bond could cause active movement of other cytoskeleton proteins that then induce cap formation.
Unusual intracellular calcium elevation is an abnormality observed in many pathological conditions including common variable immunodeficiency, systemic lupus erytheatosus (SLE), Alzheimer's disease, and brain trauma, as well as conditions resulting from toxins such as kainite and maitotoxin (Feske, 2007; Liossis et al., 1996; Saido et al., 1994; Saito et al., 1993; Tsuji et al., 1998; Lee et al., 1991; Hajimohammadreza et al., 1997; Saatman et al., 1996; Nakagawa et al., 2000) . Calcium is also known to induce active movement of cytoskeleton proteins that lead to a variety of membrane-related processes, including exocytosis, phagocytosis, membrane deformation, and capping (Oertner and Matus, 2005; Bourguignon and Pressman, 1983) . CD43 caps may therefore form in cells with elevated calcium levels, resulting in recognition and phagocytosis by macrophages. Here, we artificially elevated levels in Jurkat cells with A23187 and ionomycin, calcium ionophores, and tested whether or not elevated calcium induces CD43 capping and subsequent removal by macrophages via the carbohydratemediated mechanism.
Materials and Methods

Materials
A23187, 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acidtetrakis (acetoxymethyl) ester (BAPTA-AM), calcein-AM, ionomycin, PKH 26 red, and PKH67 green fluorescent cell linker kits were obtained from Sigma-Aldrich (St. Louis, MO, USA). Anti-CD43 mouse monoclonal antibody (clone DF-T1) and controlmouse IgG1 were obtained from DAKO (Glostrup, Denmark). Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethyl ketone (Z-VAD-fmk) was obtained from the Peptide Institute (Osaka, Japan). Anti-nucleolin antibody (anti-NUC295, an antibody against the amino acid residues 295-302 of nucleolin) was raised in rabbits and affinity purified similar to methods previously described (Eda et al., 2001) .
Oligosaccharides from human erythrocyte membrane glycoprotein (mainly band 3 glycoprotein) were prepared by hydrazinolysis of defatted human erythrocyte ghosts, as described previously (Beppu et al., 1996b) .
Treatment of Jurkat cells with A23187 or ionomycin
Jurkat cells (RIKEN Cell Bank, Tsukuba, Japan) were incubated at 4×10 6 cells/mL in RPMI 1640 medium containing 5% fetal bovine serum (FBS) with A23187 or ionomycin concentrations of 0-2 µM at 37°C in 5% CO2 atmosphere for 0-12 h.
Binding and phagocytosis assays
Binding and phagocytosis assays were employed as described previously (Eda et al., 2004) . Briefly, macrophages were generated using 50 nM phorbol myristate acetate on coverslips to differentiate THP-1 cells (Japanese Cancer Research Resources Bank, Osaka, Japan). A23187-or ionomycin-treated Jurkat cells and macrophage monolayers were co-incubated on coverslips at 37°C for 1 h with gentle shaking. After removing unbound cells, attached cells were fixed, stained, and counted. Data are expressed as the number of bound Jurkat cells/100 macrophages (minimum count of 200 macrophages).
To assay phagocytosis, A23187-treated Jurkat cells were labeled with the fluorescent cell-linker compound PKH67 (green) kit and co-incubated with macrophage monolayers as in the binding assay, after which membranes were stained with the fluorescent cell-linker compound PKH 26 (red) kit. Jurkat cells taken up by macrophages were identified using confocal laser scanning fluorescence microscopy (µ-Radiance; Bio-Rad, Hercules, USA).
Detection of cell-surface CD43
Distribution of CD43 on Jurkat cells was observed as described previously (Eda et al., 2004) . Briefly, Jurkat cells were treated with anti-CD43 antibody in RPMI 1640 medium bufferized with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (RPMI 1640-HEPES) with 0.2% bovine serum albumin (BSA) for 30 min. Washed and bound antibodies were detected using Alexa Fluoro-488 conjugated goat anti-mouse IgG (H+L) and then immediately subjected to observation via a fluorescence microscope. Throughout the immunofluorescence staining process, cell suspensions were kept at 0°C to prevent antibody-induced antigen redistribution that may occur at higher temperatures.
Detection of apoptosis in A23187-or ionomycin-treated Jurkat cells
The apoptotic states of Jurkat cells treated with A23187 or ionomycin were assessed by examining DNA fragmentation and PS expression, using commercial assay kits (MEBCYTO Apoptosis Kit and MEBSTAIN Apoptosis Kit Direct, respectively [Medical and Biological Laboratories, Nagoya, Japan]). PS expression was determined by binding fluorescein isothiocyanate-labeled annexin V (FITC-annexin V) to the cells. Briefly, Jurkat cells (2×10 5 cells) suspended in a kit buffer containing FITC-annexin V were incubated at room temperature for 15 min in the dark, in accordance with the manufacture's instruction. The cell suspension was then diluted with another buffer and immediately analyzed using a flow cytometer (FACSCalibur, Becton-Dickinson, Franklin Lakes, USA) with CELLQUEST software and gating for forward scatter (FSC) (correlating with the cell volume) and side scatter (SSC) (depending on the inner complexity of the particle) regions of intact Jurkat cells.
DNA fragmentation was assessed using TdT-mediated dUTPbiotin Nick End Labeling (TUNEL). Briefly, Jurkat cells (2×10 6 cells) were fixed with 4% paraformaldehyde at 4°C for 0.5 h. After washing with 0.2% BSA-containing DPBS(-) (0.2% BSA-DPBS [-] ), the cells were permeabilized using 70% ethanol at -20°C for 0.5 h. After washing with 0.2% BSA-DPBS(-), the DNA nick ends of cells were labeled by treatment with a kit buffer containing TdT reaction reagent at 37°C for 1 h in accordance with the manufacturer's instructions. Cells were then washed using 0.2% BSA-DPBS(-) and immediately subjected to flow cytometric analysis (FACSCalibur) with gating for FSC and SSC regions of intact Jurkat cells.
Calcein-AM treatment to A23187-treated Jurkat cells for phagocytosis assay
A23187-treated Jurkat cells were incubated with 1 µM of calcein-AM at 37°C for 20 min. The dye was removed by washing, and then the cells were subjected to the phagocytosis assay.
Binding assay for recombinant human nucleolin-expressing HEK 293 cells
Human nucleolin cDNA was transfected into the monolayer of HEK 293 cells (HEK cells; Health Science Research Bank, Osaka, Japan) as previously described (Hirano et al., 2005) . A23187-treated Jurkat cells were applied to the HEK monolayer and coincubated at 37°C for 1 h with gentle shaking. After removing unbound cells, attached cells were fixed, stained, and counted. 
Statistical analysis
The data are presented as the mean±SD of at least three experiments and analyzed using Student's t-test.
Results
Treatment with calcium ionophore A23187 induces cell-surface capping of CD43
We observed that while CD43 distribution on the surface of Jurkat cells was uniform on Jurkat cells (Fig. 1A , left panel), distribution was localized in a cap on A23187-treated Jurkat cells (Fig. 1A, right panel) . Capping required a minimum of 10 nM of A23187 (Fig. 1B) , and the largest number of capped cells was observed after treating with 100 nM for 0.5-1 h (Fig. 1C ), declining after 2 h. A similar dosage of A23187 (100 nM) has been shown to increase intracellular calcium levels from 90 nM to >10 μM in Jurkat cells (Sasaki and Hasegawa-Sasaki, 1985) . Additionally, calcium EDTA-chelation inhibited the capping of CD43 on A23187-treated cells (Fig. 1D) . These results indicate that the elevated intracellular calcium levels of A23187-treated cells led to capping of CD43, and as such, we subsequently used Jurkat cells treated with 100 nM of A23187 for 1 h unless otherwise indicated.
A23187-treated cells were recognized and phagocytosed by macrophages
We compared treatment groups and counted the number of Jurkat cells bound to macrophages as well as the number that were phagocytosed. After treatment with A23187, both the number of bound Jurkat cells ( Fig. 2A, left panel) and the number of phagocytosed Jurkat cells (right panel) increased significantly. Notably, EDTA-chelation inhibited this increase (Fig. 2B) . Taken together, these results show that A23187-treated cells with elevated calcium were recognized and phagocytosed by macrophages.
Capping of A23187-treated Jurkat cells is independent of apoptosis
We previously reported that capping of CD43 was induced during apoptosis by activated caspases (Eda et al., 2004; Miki et al., 2009) . Because A23187 is known to cause apoptosis under certain conditions (Kim et al., 2002; McConkey et al., 1989b McConkey et al., , 1989a , A23187-treated cells may also became apoptotic, thereby inducing capping. To eliminate this possibility, we examined the cells for two additional signs of apoptosis (DNA fragmentation and PS expression) and found no differences between freshly isolated Jurkat cells ( Fig. 3A and B, grey shades) and A23187-treated ones (blue lines). In contrast, both indicators were present in cells treated with 10 μM of etoposide, a drug known to induce CD43 capping through caspase-activated apoptosis (red lines). To confirm that no caspases were involved, we pretreated cells with the pan-caspase inhibitor Z-VAD-fmk, known to inhibit capping of CD43 in cells undergoing apoptosis (Fig. 3C , D and E) (Eda et al., 2004) . Z-VAD-fmk did not prevent capping of CD43 in A23187-treated Jurkat cells (Fig. 3C ) nor did it prevent the recognition and the phagocytosis of these cells by macrophages ( Fig. 3D and E) , indicating that A23187-induced capping is independent from caspase activity. While A23187 may indeed cause apoptosis under higher concentrations and with protracted treatment (Kim et al., 2002; McConkey et al., 1989b McConkey et al., , 1989a , results here indicate that calcium elevation alone induced capping of CD43 without inducing apoptosis.
AM group of calcein-AM is hydrolysed by intracellular esterases, yielding the membrane-impermeable greenfluorescent calcein. Apoptotic and dead cells with compromised cell membranes do not retain calcein. Calcein-AM is therefore used as a membrane-permeable live-cell labeling dye (Hirt et al., 2000) . A23187-treated Jurkat cells were engulfed with still intact plasma membrane, as they retained calcein during the phagocytosis procedure (Fig. 3F , upper panels and lower left panel). As shown in Fig. 3F lower right panel, the calcein-fluorescence was dispersed inside of macrophage, indicating that the phagocytosed cells were lysed by macrophages. Taken together, these observations suggest that A23187-treated cells were regarded as removal target for macrophages while still alive.
CD43 and its carbohydrate chains are the recognition ligands for A23817-treated Jurkat cells
We next investigated whether or not CD43 carbohydrate chains are the ligands for macrophage detection of A23187-treated cells. Macrophage recognition was inhibited in Jurkat cells pretreated with anti-CD43 antibody (Fig. 4A) , indicating that CD43 is the ligand. Further, poly-N-acetyllactosaminyl carbohydrates containing oligosaccharides prepared from human erythrocyte membranes (Beppu et al., 1996b ) also inhibited the recognition (Fig. 4B) , indicating that recognition likely occurs through the poly-N-acetyllactosaminyl chains on the CD43 caps.
Nucleolin is the macrophage receptor for A23187-treated Jurkat cells CD43-capped apoptotic cells are known to be recognized by nucleolin (Hirano et al., 2005; Miki et al., 2009 Miki et al., , 2007 , and we confirmed that this was the case in A23187-treated CD43-capped Jurkat cells. First, macrophages were inhibited from binding to A23187-treated Jurkat cells by pretreatment with anti-nucleolin antibody, while control rabbit IgG was ineffective (Fig. 5A) . Additionally, we induced expression of recombinant nucleolin on the surface of nonmacrophage HEK cells as described previously (Hirano et al., 2005) and found that more A23187-treated Jurkat cells bound to these HEK cells than to non-transfected HEK cells (Fig. 5B) , and that binding was inhibited by oligosaccharides prepared from human erythrocytes (Fig. 5C ). These results clearly indicate that nucleolin is the receptor for A23187-treated Jurkat cells.
CD43-mediated recognition of ionomycin-treated Jurkat cells
Ionomycin is also used as a calcium ionophore to trigger calcium-increase in Jurkat cells (Nair et al., 2006) . We next tested whether or not elevated calcium with ionomycin induces CD43 capping and subsequent recognition by macrophages via the CD43-mediated mechanism. We observed that while CD43 distribution on the surface of Jurkat cells was uniform on Jurkat cells (Fig. 6A, upper panel) , distribution was localized in a cap on ionomycin-treated Jurkat cells (Fig. 6A, lower panel) . Capping required a minimum of 20 nM of ionomycin (Fig. 6B) . Because ionomycin is known to cause apoptosis under certain conditions (Gil-Parrado et al., 2002) , we examined PS expression on 20 nM or 2 μM ionomycin-treated cells. We hardly found a difference between ionomycin-untreated Jurkat cells (Fig. 6C , grey shades) and 20 nM ionomycin-treated ones (blue line). In contrast, PS expression was increased in cells treated with 2 μM of ionomycin (red line). Indicating that 20 nM of ionomycin-treatment induced capping of CD43 without inducing apoptosis. In addition, ionomycin-treated Jurkat cells were recognized by macrophages, and the recognition was inhibited by pretreatment with anti-CD43 antibody (Fig. 6D) . Imboden et al. reported that >5 nM of ionomycintreatment increase intracellular calcium levels in Jurkat cells (Imboden et al., 1985) . Additionally, BAPTA-AM, an intracellular calcium chelator, -treatment inhibited the recognition (Fig. 6E) . These results indicating that ionomycintreated cells with elevated calcium were also recognized by macrophages via the CD43-mediated mechanism.
Discussion
Here we demonstrated that Jurkat cells with artificially raised calcium levels were recognized and phagocytosed by macrophages through the interaction between the cellsurface poly-N-acetyllactosaminyl carbohydrate chains of CD43 and the macrophage receptor nucleolin. Further, these cells were removed while still alive, indicating that calcium elevation alone can cause a cell to be regarded by macrophages as a target for removal. Although many details regarding the mechanism by which macrophages recognize apoptotic cells are known, how they recognize live-butdeteriorating cells is poorly understood. This study sheds light on the latter process and highlights the important role of CD43 capping with poly-N-acetyllactosaminyl carbohydrate chains. These findings contribute to the broader understanding of biological defense mechanisms.
We used A23187 to induce elevated calcium levels in our Jurkat cells. Indeed, A23187 are often used in the laboratory to increase intracellular calcium (Sasaki and HasegawaSasaki., 1985; Minetti et al., 1996) . Additionally, when treated with Ca 2+ and A23187, human erythrocytes and lymphocytes respond by budding to release membrane vesicles (Allan and Michell, 1975; Allan et al., 1976a; PodszywalowBartnicka et al., 2007) . This treatment also induces several other biochemical changes, including K + efflux (Lew and Ferreira, 1976; Dupuis et al., 1989) , the breakdown of polyphosphoinositides, a rise in 1,2-diacylglycerol and phosphatidate concentrations (Allan et al., 1976b; Allan and Michell, 1978; Ponnappa et al., 1980; Allan and Thomas, 1981; Butikofer et al., 1993) , and a selective loss of glycosylphosphatidylinositol-anchored membrane proteins (Butikofer et al., 1993) . The treatment of hematopoietic cells with A23187 can thus be regarded as a model with which to investigate the biochemical mechanisms responsible for membrane composition during intracellular calcium elevation. Although we showed that cells with elevated calcium levels developed CD43 caps on the cell surface, currently we are unable to explain the capping mechanism definitively. However, studies have shown that increased intracellular calcium induces CD32 and CD44 to form patches or caps (Roberts et al., 1997; Bourguignon et al., 1993) . Authors speculated that CD44 formed caps through the activity of the calcium ionophore ionomycin as follows: Increased calcium binds to calmodulin, Ca/calmodulin induces phosphorylation of myosin L chains, the membrane-associated actomyosin contractile-system is engaged, and CD44 forms caps (Bourguignon et al., 1993) . Cytoskeletal proteins may therefore play a critical role in ligand capping in cells with elevated calcium. Our previous research also suggests that active movement of cytoskeleton proteins may induce CD43 capping when caspases are activated (Eda et al., 2004; Oguri et al., 2012) . Activated caspases can abrogate the link between CD43 and actin during the early stages of apoptosis (Kondo et al., 1997) , and disrupting the actin bond presumably causes active movement of other cytoskeleton proteins that then induce capping of CD43 (Eda et al., 2004; Oguri et al., 2012) . However, while the capping of CD43 on etoposide-treated cells is inhibited by Z-VAD-fmk, this is not the case with A23187-treated cells, indicating that the bond can be disrupted by other means (Oertner and Matus, 2005; Bourguignon and Pressman, 1983) . Although acti- vated caspases sever the link between CD43 and actin, calcium influx may also disturb this important connection. Alternatively, since increased calcium is known to induce active movement of cytoskeleton proteins that can lead a capping (Oertner and Matus, 2005; Bourguignon and Pressman, 1983) , even if the CD43-actin bond is not severed, stronger active movement of other cytoskeleton proteins triggered by excessive calcium influx may induce CD43 capping. Thus, disrupting the balance of tension between CD43 and cytoskeleton proteins is thought to be a key factor in cap formation. Further investigation is needed to illuminate the precise details of the capping mechanism.
Capping or clustering of CD43 is found in interactions between neutrophil cells and vasclcular endothelial cells that are treated with chemotaxis factors such as N-formylmethionyl-leucyl-phenylalanine, N-formyl-norleucyl-leucylphenylalanyl-norleucyl-tyrosyl-lysine, and IL-8, resulted in neutrophil-chemotax to outside of blood vessel (AlonsoLebrero et al., 2000; Seveau et al., 2001; Dehghani Zadeh et al., 2003) . These findings supporting the idea that capping of CD43 induce cell-cell interactions. However, how the capping of CD43 causes various physiologic activities is not fully understood P-selectin glycoprotein ligand-1 and intracellular adhesion molecule-3 exist in the area of capped CD43 of chemotactic neutrophil (Alonso-Lebrero et al., 2000; Seveau et al., 2001; Dehghani Zadeh et al., 2003) . The composition of the molecules that work together in CD43 cap formation may influence the physiologic activities.
The mechanism by which macrophages recognize cells with elevated calcium is poorly understood. Using A23187-treated human erythrocytes and lymphocytes, Balasubramanian et al. revealed that sustained elevation in cytosolic Ca 2+ leads to outward movement of plasma-membrane PS (Balasubramanian et al., 2007) , which has since been presumed to cause the proteolytic degradation of cytoskeletal proteins seen after increases in intracellular calcium (Verhallen et al., 1987 (Verhallen et al., , 1988 Bevers et al., 1983) . Because PS is already a well-known ligand for macrophage recognition (Savill et al., 1993; Savill and Fadok, 2000; Fadok et al., 2001; Platt et al., 1998; Eda et al., 2004) , these previous findings suggest it to be the relevant ligand for the recognition of cells with elevated calcium levels.
Understanding how cells with elevated calcium are removed is important because increased intracellular calcium is a symptom of several pathologies, including Alzheimer's disease and SLE. These diseases may be ameliorated or prevented by the removal of harmful cells (Feske, 2007; Liossis et al., 1996; Saido et al., 1994; Saito et al., 1993; Tsuji et al., 1998; Lee et al., 1991; Hajimohammadreza et al., 1997; Saatman et al., 1996; Nakagawa et al., 2000) . Indeed, amyloid β induces calcium influx into neurons which in turn can cause neurotoxicity (apoptosis) that results in Alzheimer's disease (Ho et al., 2001) . Milk fat globule epidermal growth-factor 8 (MFG-E8), which initially attaches to PS on apoptotic cells and then forms a link with phagocytes to initiate or augment phagocytosis (Hanayama et al., 2002) , may prevent Alzheimer's disease in the brain via microglia that aid in clearing amyloid β-induced apoptotic neurons (Fuller and Van Eldik, 2008) . Additionally, PS-MFG-E8-mediated clearance also prevents SLE (Hanayama et al., 2004) . Just as both the PS and capped-CD43 pathways lead to successful removal of deteriorating (apoptotic) cells , we propose that in addition to PS-mediated removal, Alzheimer's disease and SLE may also be prevented by carbohydrate-mediated removal of cells with elevated calcium in the early stage before cells die.
Nucleolin was confirmed as the receptor for the CD43 caps on calcium-elevated cells. Nucleolin is present in the nucleus, cytoplasm, and on the surface of some types of cells including macrophages (Ginisty et al., 1999; Nigg, 1997) . Previous studies have shown that macrophages utilize nucleolin to recognize and phagocytose apoptotic and oxidized cells (Hirano et al., 2005; Miki et al., 2009) as well as living cells that have been treated with cytochalasin B (Oguri et al., 2012) . Nucleolin-mediated recognition by macrophages is therefore simple and powerful, as indicated by the indiscriminant removal of capped cells. Nucleolin is also a receptor for lipoproteins (Semenkovich et al., 1990) , coxsackie B virus (de Verdugo et al., 1995) , human immunodeficiency virus , human parainfluenza virus type 3 (Bose et al., 2004) , and enterohemorrhagic Escherichia coli O157:H7 (Sinclair and O'Brien, 2002) . Further, nucleolin can bind to anionic molecules such as DNA, RNA (Jordan, 1987; Nigg, 1997) , and, as confirmed here, poly-N-acetyllactosaminyl chains. Taken together, these observations suggest that nucleolin on the surface of macrophages may have a general scavenger receptor-like ability.
Several studies have reported that nucleolin forms spotlike aggregations on cell surfaces Sinclair and O'Brien, 2002) . We also observed this phenomenon on nucleolin-transfected HEK cells (data not shown). The three-dimensional structure of the CD43 cap may therefore be critical for multivalent binding with aggregated nucleolin and might also explain why macrophages cannot recognize CD43 if the protein is uniformly distributed (Oguri et al., 2012) .
Here we revealed that increased intracellular calcium induces capping of CD43 and removal by macrophages. Increases in intracellular calcium occur in diverse pathologies including SLE, cancer, common variable immunodeficiency glutamate, kainite, maitotoxin, brain trauma, and neurodegenerative processes such as Alzheimer's disease (Feske, 2007; Liossis et al., 1996; Saido et al., 1994; Saito et al., 1993; Tsuji et al., 1998; Lee et al., 1991; Hajimohammadreza et al., 1997; Saatman et al., 1996; Nakagawa et al., 2000) . Although these are critical diseases, more details are required to understand them fully. If calcium-elevation causes these diseases, disruption of our clearance-mechanism may be involved in the development of these diseases. Therefore, the mechanism may be performed as physiological defense mechanism against calcium-elevation. In contrast, the mechanism may be involved in the aggravation of these diseases and complication with hypercalcemia, such as renal insufficiency, by removal of cells (Ossareh, 2011) . Our present findings may contribute to the broader understanding of developmental mechanisms and thus medical treatment or prevention of these diseases. Further study for the removal mechanism of calcium-elevated cells is necessary for better understanding of the disease with calciumelevation and tissue homeostasis.
